Neurocrine Q3 Revenue Tops $1.1B, INGREZZA Guidance Raised to $2.9-$2.925B
NBIX sits 19% above its 52-week low of $122.138.
Summary
Neurocrine reported Q3 2026 revenue of $1.123 billion, up 41%, with INGREZZA sales of $801 million. Full-year INGREZZA guidance rose to $2.9-$2.925 billion and SG&A guidance came down, lifting Non-GAAP EPS to $3.29 from $2.17.
Key Events · Earnings and Guidance · NBIX
-
Q3 Revenue Tops $1.1 Billion
Total revenues reached $1,123 million versus $795 million a year earlier, 41% growth, as net product sales exceeded $1 billion for the first time.
-
INGREZZA Guidance Raised Again
Full-year 2026 INGREZZA net sales guidance increased to $2.900-$2.925 billion from $2.825-$2.875 billion; Q3 INGREZZA sales were $801 million, up 17%.
-
SG&A Outlook Cut, EPS Jumps
GAAP SG&A guidance was lowered to $1,540-$1,560 million and Non-GAAP to $1,290-$1,310 million; Non-GAAP diluted EPS rose to $3.29 from $2.17.
-
Cash Falls After Soleno Deal
Cash, equivalents and marketable securities totaled $790 million at September 30, 2026 versus $2,543 million at December 31, 2025, after the May 2026 Soleno acquisition added $2.2 billion of VYKAT XR intangibles.
Analysis · NBIX · Life Sciences
For the first time, Neurocrine crossed $1 billion in quarterly net product sales, with total revenue up 41% to $1.123 billion. Full-year INGREZZA guidance was raised by $75 million at the midpoint and the SG&A outlook was cut, so more of each sales dollar reaches the bottom line — Non-GAAP EPS jumped to $3.29 from $2.17 a year ago. The offset is cash: $790 million on hand versus $2.543 billion at year-end 2025, reflecting the May 2026 Soleno acquisition and the $2.2 billion of VYKAT XR intangible now being amortized. Management pointed to 2027 Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, with an R&D Day set for December 15, 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NBIX was trading at $145.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8B. The 52-week trading range was $122.14 to $186.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.